Literature DB >> 9481622

Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides.

O Ashur-Fabian1, E Giladi, D E Brenneman, I Gozes.   

Abstract

Vasoactive intestinal peptide (VIP) has been shown to be a potent promoter of neuronal survival. Pituitary adenylate cyclase-activating peptide (PACAP), a homologous peptide, shares activity and receptor molecules with VIP. The neuroprotective effects of VIP have been shown to be mediated via astroglial-derived molecules. Utilizing a battery of antisense oligodeoxynucleotides directed against the multiple cloned VIP-preferring (VIP receptors 1 and 2) or PACAP-preferring receptors (six splice variants derived from the same gene transcript), the authors have demonstrated the existence of a specific PACAP receptor splice variant (PACAP4 or hop2) on astrocytes as well as a VIP type2 receptor. The identification of the receptors was achieved by incubation of the cells in the presence of the specific antisense oligodeoxynucleotide followed by radiolabeled VIP binding and displacement. Polymerase chain reaction (PCR) coupled to direct sequencing identified the expression of the PACAP4-hop2 receptor splice variant in astrocytes. Neuronal survival assays were conducted in mixed neuronal-glial cultures derived from newborn rat cerebral cortex. When these cultures were exposed to the battery of the antisense oligodeoxynucleotides, in serum-free media, only the PACAP-specific ones (e.g., hop2-specific) had an effect in decreasing neuronal cell counts. Thus, the VIP neuronal survival effect is mediated, at least in part, via a specific PACAP receptor (containing a unique insertion of 27 amino acids--the hop2 cassette). These data indicate that a hop2-like PACAP/VIP receptor is the receptor that mediates neurotropism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9481622     DOI: 10.1007/BF02800503

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  50 in total

1.  Cytokine regulation of neuronal survival.

Authors:  D E Brenneman; M Schultzberg; T Bartfai; I Gozes
Journal:  J Neurochem       Date:  1992-02       Impact factor: 5.372

2.  An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.

Authors:  I Gozes; S K McCune; L Jacobson; D Warren; T W Moody; M Fridkin; D E Brenneman
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

3.  Slow excitatory postsynaptic currents mediated by N-methyl-D-aspartate receptors on cultured mouse central neurones.

Authors:  I D Forsythe; G L Westbrook
Journal:  J Physiol       Date:  1988-02       Impact factor: 5.182

4.  Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.

Authors:  I Gozes; G Lilling; R Glazer; A Ticher; I E Ashkenazi; A Davidson; S Rubinraut; M Fridkin; D E Brenneman
Journal:  J Pharmacol Exp Ther       Date:  1995-04       Impact factor: 4.030

5.  Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells.

Authors:  Y Wollman; G Lilling; M N Goldstein; M Fridkin; I Gozes
Journal:  Brain Res       Date:  1993-10-08       Impact factor: 3.252

6.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

Authors:  T B Usdin; T I Bonner; E Mezey
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

7.  Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment.

Authors:  I Gozes; A Reshef; D Salah; S Rubinraut; M Fridkin
Journal:  Endocrinology       Date:  1994-05       Impact factor: 4.736

8.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

Authors:  T W Moody; F Zia; M Draoui; D E Brenneman; M Fridkin; A Davidson; I Gozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

9.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

Authors:  T Ishihara; R Shigemoto; K Mori; K Takahashi; S Nagata
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173

10.  Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide.

Authors:  D E Brenneman; E A Neale; G A Foster; S W d'Autremont; G L Westbrook
Journal:  J Cell Biol       Date:  1987-06       Impact factor: 10.539

View more
  14 in total

1.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

2.  Augmented cystine-glutamate exchange by pituitary adenylate cyclase-activating polypeptide signaling via the VPAC1 receptor.

Authors:  Jon M Resch; Rebecca Albano; Xiaoqian Liu; Julie Hjelmhaug; Doug Lobner; David A Baker; Sujean Choi
Journal:  Synapse       Date:  2014-08-06       Impact factor: 2.562

Review 3.  A new concept in the pharmacology of neuroprotection.

Authors:  I Gozes; D E Brenneman
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

4.  Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.

Authors:  I Gozes; O Perl; E Giladi; A Davidson; O Ashur-Fabian; S Rubinraut; M Fridkin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 5.  Physiology of Astroglia.

Authors:  Alexei Verkhratsky; Maiken Nedergaard
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

6.  Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38.

Authors:  Min Li; Csaba David; Toshiteru Kikuta; Aniko Somogyvari-Vigh; Akira Arimura
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

7.  Cerebellar cortical-layer-specific control of neuronal migration by pituitary adenylate cyclase-activating polypeptide.

Authors:  D B Cameron; L Galas; Y Jiang; E Raoult; D Vaudry; H Komuro
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

8.  Vasoactive intestinal polypeptide entrains circadian rhythms in astrocytes.

Authors:  Luciano Marpegan; Thomas J Krall; Erik D Herzog
Journal:  J Biol Rhythms       Date:  2009-04       Impact factor: 3.182

Review 9.  PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Giuseppe Musumeci; Dora Reglodi; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

10.  A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.

Authors:  A Sharma; J Walters; Y Gozes; M Fridkin; D Brenneman; I Gozes; T W Moody
Journal:  J Mol Neurosci       Date:  2001-12       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.